CoronaryAtlas logo
CoronaryAtlas
Carnitine
Pathway / Myocardial injury (shared endpoint)

Carnitine

metabolite

Carnitine concentration changes reflect myocardial fatty-acid oxidation and energetic stress during acute myocardial infarction.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencehigh
RationaleEarly AMI risk biomarker; myocardial fatty-acid-oxidation substrate.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
0
C — non-Type-I
56
A — assay feasibility
42
E — evidence strength
66
T1DI (composite)
6
Specificity differential (R−C)-55.6
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 1
2hypertensive emergencyn/a
2high-demand / peri-operative stressmag 1
3sudden cardiac deathmag 3
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 1
Coverage: 6/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 15 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(1)

Clinical trials(1)